CLINICAL_TRIALS
research
· 2025-10-09
Clinical Trial Update: A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis [Phase 2, Phase 3]
Summary
A sequential Phase 2/3 trial of APL2 is planned for focal segmental glomerulosclerosis and is currently not recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: FSGS | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING